Aripiprazole in Children With Autism: A Pilot Study
This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism.
Children who qualify for the study will be treated with aripiprazole for 6 weeks.
Treatment is provided at no cost.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Aripiprazole in Children With Autism: A Pilot Study|
- Clinical Global Impressions [ Time Frame: Week 6 ] [ Designated as safety issue: No ]
- Children's Psychiatric Rating Scale [ Time Frame: Baseline, Week 6 ] [ Designated as safety issue: No ]
|Study Start Date:||February 2004|
|Study Completion Date:||December 2008|
|Primary Completion Date:||December 2008 (Final data collection date for primary outcome measure)|
1 Open Label
Open Label Aripiprazole
Aripiprazole 5 mg to 30mg, individually titrated
Other Name: Abilify
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00208533
|United States, Pennsylvania|
|Drexel University College of Medicine at Friends Hospital|
|Philadelphia, Pennsylvania, United States, 19124|
|Principal Investigator:||Richard P Malone, MD||Drexel University College of Medicine|